<DOC>
	<DOCNO>NCT00679315</DOCNO>
	<brief_summary>The purpose study explore efficacy Alfuzosin ( 10 mg , qd ) reduce score International Prostate Symptom Score ( IPSS ) baseline 8 week treatment female patient void dysfunction .</brief_summary>
	<brief_title>Efficacy Safety Alfuzosin Treatment Voiding Dysfunction Female</brief_title>
	<detailed_description>Trial design Phase II , multi-center , randomize , double-blind , placebo-controlled , parallel group study evaluate clinical efficacy safety alfuzosin ( 10mg , qd ) baseline 8 week treatment female patient non-neurogenic voiding dysfunction . Efficacy Assessment 1 . Primary efficacy endpoint Actual change score IPSS baseline 8 week treatment . 2 . Secondary efficacy endpoint - IPSS parameter - Percent change score IPSS baseline 4 8 week treatment . - Actual percent change sub-scale IPSS baseline 4 8 week treatment - Storage score : sum question 2 , 4 7 - Voiding score : sum question 1 , 3 , 5 6 - Scored form Bristol Female Lower Urinary Tract Symptoms ( BFLUTS-SF ) parameters - Actual Percent change BFLUTS-SF baseline 4 8 week treatment . - Actual percent change sub-scale BFLUTS-SF baseline 4 8 week treatment - BFLUTS-FS : sum score F1-F4 - BFLUTS-VS : sum score V1-V3 - BFLUTS-IS : sum score I1-I5 - BFLUTS-sex : sum score S1 &amp; S2 - Uroflowmetry &amp; PVR parameters - Numeric percent change baseline 4 8 week treatment . - Maximum flow rate ( mL/s ) - Average flow rate ( mL/s ) - Post-void residual urine ( mL ) - Micturition diary parameter - Change mean number micturition per 24 hour week 4 8 relative baseline - Percent change micturition per 24 hour week 4 8 relative baseline - Change mean number nighttime micturition per 24 hour week 4 8 relative baseline - Percent change nighttime micturition per 24 hour week 4 8 relative baseline - Change mean number urgency episodes per 24 hour week 4 8 relative baseline ( Urgency episode define Bladder Sensation Scale rating ≥ 3 diary ) . - Percent change urgency episodes per 24 hour week 4 8 relative baseline - Change mean sum rating Bladder Sensation Scale week 4 8 relative baseline - Quality life ( QoL ) parameter - Change Bother score IPSS baseline 4 8 week treatment . - Change QOL subscale score BFLUTS SF baseline 4 8 week treatment - BFLUTS-QoL : Sum score QoL1-QoL5 - Patient Perception Bladder Condition ( PPBC ) - Change baseline PPBC 8 week double-blind treatment - Benefit , Satisfaction , Willingness Continue ( BSW ) Questions - Patient Perception Treatment Benefit week 8 - Patient Perception Treatment Satisfaction week 8 - Willingness continue treatment week 8</detailed_description>
	<mesh_term>Alfuzosin</mesh_term>
	<criteria>Female age ≥ 18 Have void symptom chief complaint 3 month IPSS symptom score ≥ 15 A peak flow rate &lt; 12 mL/sec minimum void volume 100 mL and/or postvoid residual urine volume &gt; 150 mL Underwent pressureflow study Patients meet follow criterion exclude study : Neurogenic void dysfunction Anatomic cause bladder outlet obstruction Perform physical examination patient diagnose BOO pressureflow study urethral evaluation 16 Fr urethral sound : resistance 16Fr sound , diagnose anatomical BOO patient participate study . Previous surgical procedure relate incontinence cystocele Pregnant nursing woman Intake medication drug affect bladder function : alpha blocker , anticholinergic Anticholinergic drug : Tolterodine , Oxybutynin , Propiverin , Trospium , Solifenacin , SSRI include TCA Cholinergic drug : Bethanechol Any blocker alfuzosin patient enrol washout Any positive urine culture successfully treat recruitment . Clinically significant ( ≥ Stamey grade II/III ) stress incontinence determine investigator confirm female patient cough provocation test . Recurrent UTIs define treat symptomatic UTIs ≥ 4 time last year Diagnosed suspected interstitial cystitis Patients mark cystocele clinically significant pelvic prolapse . Treatment within 14 day precede randomization , expect initiate treatment study : Estrogen treatment start 2 month prior inclusion allow Receipt electrostimulation bladder training within 14 day randomization , expect start treatment study . Hypersensitive study drug Orthotopic hypotension history orthotopic hypotension Intake calcium channel blocker Severe hepatic renal dysfunction</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>female void dysfunction</keyword>
	<keyword>alpha adrenoreceptor antagonist</keyword>
	<keyword>IPSS American Urological Association symptom index</keyword>
</DOC>